After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

Group 1 - Sagimet Biosciences Inc. (SGMT) has experienced a significant decline of 28% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for SGMT is currently at 29.42, suggesting that the heavy selling pressure may be exhausting itself [5] - There is a strong consensus among Wall Street analysts that SGMT will report better earnings than previously predicted, with a 13.2% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - SGMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8]